ClinicalTrials.gg

Program

Dextromethorphan/Bupropion Tablet AXS-05

Also written as “AXS-05”, “AXS-05 (dextromethorphan-bupropion)” and “AXS-05 (dextromethorphan and bupropion) oral tablets”.

Its studies are mostly in Alzheimer Disease · Depressive Disorder, Major · Depressive Disorder, Treatment-Resistant · Smoking Cessation · Depression, led by Axsome Therapeutics.

Furthest: phase 4, since Jan 16, 202414 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Axsome Therapeutics142 open or runningphase 4since Jan 16, 2024Apr 5, 2016Dec 2027phase 3 · NCT07766655

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 5, 2016First study: phase 3 study in Depressive Disorder, MajorFirst studyNCT02741791 · 312 enrolled · United States
  2. Jul 20, 2017Phase 3 study in Alzheimer DiseaseNCT03226522 · 366 enrolled · United States, Australia
  3. Jun 20, 2018Phase 2 study in Depressive Disorder, MajorNCT03595579 · 97 enrolled · United States
  4. Jul 11, 20192 phase 3 studiesNCT04019704, NCT04039022
  5. Oct 7, 2020Phase 2 study in Depressive Disorder, Treatment-ResistantNCT04608396 · 44 enrolled · United States
  6. Nov 12, 2020Phase 2 study in Depressive Disorder, Treatment-ResistantNCT04634669 · 181 enrolled · United States
  7. Mar 5, 2021Phase 3 study in Alzheimer DiseaseNCT04797715 · 178 enrolled · United States, Canada
  8. Jun 24, 2021Phase 3 study in Alzheimer DiseaseNCT04947553 · 456 enrolled · United States, Canada, Puerto Rico
  9. Jul 12, 2021Phase 2 study in Depressive Disorder, MajorNCT04971291 · 312 enrolled · United States
  10. Sep 23, 2022Phase 3 study in Alzheimer DiseaseNCT05557409 · 408 enrolled · United States, Puerto Rico
  11. Jan 16, 2024Phase 4 study in Depressive Disorder, MajorNCT06223880 · 350 planned · United States
  12. Dec 12, 2024Phase 3 study in Alzheimer DiseaseNCT06736509 · 139 enrolled · United States, Puerto Rico
  13. Aug 11, 2026Phase 3 study in Smoking CessationNCT07766655 · 705 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 3 study in Smoking CessationNCT07766655

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07766655Smoking Cessation · United States3RecruitingDec 2027705
NCT06736509Alzheimer Disease · United States, Puerto Rico3TerminatedFeb 17, 2025139
NCT06223880Depressive Disorder, Major · United States4RecruitingMar 2026350
NCT05557409Alzheimer Disease · United States, Puerto Rico3CompletedNov 21, 2024408
NCT04971291Depressive Disorder, Major · United States2UNKNOWNJul 2021312
NCT04947553Alzheimer Disease · United States, Canada, Puerto Rico3CompletedDec 3, 2024456
NCT04797715Alzheimer Disease · United States, Canada3CompletedNov 21, 2022178
NCT04634669Depressive Disorder, Treatment-Resistant · United States2TerminatedFeb 18, 2022181
NCT04608396Depressive Disorder, Treatment-Resistant · United States2CompletedJul 30, 202144
NCT04039022Depressive Disorder, Major · United States3CompletedOct 23, 2020876
NCT04019704Depression · United States3CompletedNov 26, 2019327
NCT03595579Depressive Disorder, Major · United States2CompletedJan 7, 201997
NCT03226522Alzheimer Disease · United States, Australia3CompletedApr 17, 2020366
NCT02741791Depressive Disorder, Major · United States3CompletedMar 20, 2020312

How it is read

Names in the registry

  • “AXS-05”, 9 entries
  • “AXS-05 (dextromethorphan-bupropion)”, 4 entries
  • “AXS-05 (dextromethorphan and bupropion) oral tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Dextromethorphan/Bupropion Tablet AXS-05 (Axsome Therapeutics): development program | ClinicalTrials.gg